abstract: ANTI-PD-1 ANTIBODIES THERAPEUTIC USE IN LYMPHOID NEOPLASMS: Immune checkpoints blockade is under investigation in oncology, and has demonstrated its clinical efficacy. In hematology, immune checkpoints blockade is in earlier stages of development, but there are strong evidences of PD-1 blockade anti-tumor efficacy in some lymphoid malignancies. In this review, we will discuss the main clinical results of PD-1 inhibitors in lymphoid neoplasms and the main perspectives of development.
authors.affiliation: Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
authors.forename: Laura
authors.initials: L
authors.lastname: Bounaix
authors.affiliation: Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Bendouda
authors.affiliation: Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.affiliation: Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France. Electronic address: rlemal@chu-clermontferrand.fr.
authors.forename: Richard
authors.initials: R
authors.lastname: Lemal
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000628:therapy*; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000069283:Rituximab / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; D000069283:Rituximab; C585832:pidilizumab; C582435:pembrolizumab
keywords: Lymphoma; Lymphome; Nivolumab; PD-1